NEW YORK, April 5 (Reuters) - Two prominent U.S. heart experts said studies of Merck & Co. Inc. arthritis drug Arcoxia revealed risks that should prevent its approval in the United States and that the drug poses unacceptable dangers in the 63 countries where it is already sold.
